,docid,isValid,passage,passageid
0,HPRD50.d0,False,Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III,HPRD50.d0.s0
1,HPRD50.d0,False,Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III,HPRD50.d0.s0
2,HPRD50.d0,False,Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III,HPRD50.d0.s0
3,HPRD50.d1,True,"Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2",HPRD50.d1.s0
4,HPRD50.d1,False,"The receptor binding site of MCP-1 also is significantly different from the binding sites of RANTES and IL-8, providing insight into the issue of receptor specificity",HPRD50.d1.s1
5,HPRD50.d1,False,"The receptor binding site of MCP-1 also is significantly different from the binding sites of RANTES and IL-8, providing insight into the issue of receptor specificity",HPRD50.d1.s1
6,HPRD50.d1,False,"The receptor binding site of MCP-1 also is significantly different from the binding sites of RANTES and IL-8, providing insight into the issue of receptor specificity",HPRD50.d1.s1
7,HPRD50.d1,True,It was previously shown that the N-terminus of CCR2 is critical for binding MCP-1,HPRD50.d1.s2
8,HPRD50.d1,True,"To identify the regions of MCP-1 that contact its receptor, CCR2, we substituted all surface-exposed residues with alanine",HPRD50.d1.s3
9,HPRD50.d2,False,We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer,HPRD50.d2.s0
10,HPRD50.d2,False,We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer,HPRD50.d2.s0
11,HPRD50.d2,False,We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer,HPRD50.d2.s0
12,HPRD50.d2,False,The formation of a functional single chain/subunit complex was not restricted to the FSH single chain/CG beta subunit since CG single chain interacts with the monomeric FSH beta subunit and exhibits FSH activity,HPRD50.d2.s1
13,HPRD50.d2,False,"This is relevant for the case of LH and FSH, because both are synthesized in the same cell (i.e., pituitary gonadotrophs) and several of the alpha subunit sequences required for association with either the LH beta or FSH beta subunits are different",HPRD50.d2.s2
14,HPRD50.d2,False,"Previously, we showed that the CG beta or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, CG beta alpha and F beta alpha, respectively",HPRD50.d2.s3
15,HPRD50.d2,False,"Previously, we showed that the CG beta or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, CG beta alpha and F beta alpha, respectively",HPRD50.d2.s3
16,HPRD50.d2,False,"Previously, we showed that the CG beta or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, CG beta alpha and F beta alpha, respectively",HPRD50.d2.s3
17,HPRD50.d3,True,"Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines",HPRD50.d3.s0
18,HPRD50.d3,False,RESULTS: Tyrosine phosphorylation of p85 is upregulated by IL-6 in both LNCaP and PC-3,HPRD50.d3.s1
19,HPRD50.d3,True,"IL-6 promotes coprecipitation of p85 with gp130, the signal-transducing component of the IL-6 receptor",HPRD50.d3.s2
20,HPRD50.d3,False,"IL-6 promotes coprecipitation of p85 with gp130, the signal-transducing component of the IL-6 receptor",HPRD50.d3.s2
21,HPRD50.d3,False,"IL-6 promotes coprecipitation of p85 with gp130, the signal-transducing component of the IL-6 receptor",HPRD50.d3.s2
22,HPRD50.d4,False,"In solution, FGFR4ed formed complexes with acidic FGF (FGF-1) and basic FGF (FGF-2), both in the presence and absence of heparin",HPRD50.d4.s0
23,HPRD50.d4,False,Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2,HPRD50.d4.s1
24,HPRD50.d4,True,Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2,HPRD50.d4.s1
25,HPRD50.d4,False,Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2,HPRD50.d4.s1
26,HPRD50.d4,True,Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2,HPRD50.d4.s1
27,HPRD50.d4,False,Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2,HPRD50.d4.s1
28,HPRD50.d4,True,Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2,HPRD50.d4.s1
29,HPRD50.d5,True,Cytohesin-1 regulates beta-2 integrin-mediated adhesion through both ARF-GEF function and interaction with LFA-1,HPRD50.d5.s0
30,HPRD50.d5,True,"Here we provide evidence of how cytohesin-1, an integrin-binding protein and guanine-nucleotide exchange factor (GEF) for ARF GTPases, regulates cell adhesion",HPRD50.d5.s1
31,HPRD50.d5,True,"Mutational analyses of the beta-2 cytoplasmic domain revealed that the adhesive function of LFA-1 depends on its interaction with cytohesin-1, unless the integrin is activated by exogenous divalent cations",HPRD50.d5.s2
32,HPRD50.d5,True,"Secondly, cytohesin-1 induces expression of an extracellular activation epitope of LFA-1, and the exchange factor function is not essential for this activity",HPRD50.d5.s3
33,HPRD50.d5,True,"In contrast, LFA-1-mediated cell adhesion and spreading on intercellular cell adhesion molecule 1 is strongly inhibited by a cytohesin-1 mutant, which fails to catalyze ARF GDP-GTP exchange in vitro",HPRD50.d5.s4
34,HPRD50.d5,True,"Thus, cytohesin-1 is involved in the activation of LFA-1, most probably through direct interaction with the integrin, and induces cell spreading by its ARF-GEF activity",HPRD50.d5.s5
35,HPRD50.d7,True,Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2,HPRD50.d7.s0
36,HPRD50.d7,False,"Deletion analysis showed that the element responsible for the PPARgamma effect is located in a region containing the nuclear factor E2 (NF-E2)/AP-1 site (-98/-88), which was indicated to be the major promoter of the TXS gene",HPRD50.d7.s1
37,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)",HPRD50.d7.s2
38,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)",HPRD50.d7.s2
39,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)",HPRD50.d7.s2
40,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)",HPRD50.d7.s2
41,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)",HPRD50.d7.s2
42,HPRD50.d7,False,"By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)",HPRD50.d7.s2
43,HPRD50.d7,False,"Finally, a direct interaction between PPARgamma and NRF2 was confirmed by glutathione S-transferase pull-down assay",HPRD50.d7.s3
44,HPRD50.d8,False,"By constructing deletion mutants, we identified that amino acid residues 229-309 of Akt were involved in the binding to Hsp90 and amino acid residues 327-340 of Hsp90beta were involved in the binding to Akt",HPRD50.d8.s0
45,HPRD50.d9,False,"Here, we cloned and characterized a mouse orthologue of human KIAA1427 protein as an atypical Syt (named Syt XIII)",HPRD50.d9.s0
46,HPRD50.d9,False,"Here, we cloned and characterized a mouse orthologue of human KIAA1427 protein as an atypical Syt (named Syt XIII)",HPRD50.d9.s0
47,HPRD50.d9,False,"Here, we cloned and characterized a mouse orthologue of human KIAA1427 protein as an atypical Syt (named Syt XIII)",HPRD50.d9.s0
48,HPRD50.d9,False,"Subcellular fractionation and antibody-uptake experiments indicate that Syt XIII is indeed a type-I membrane protein, but, unlike other Syt isoforms, lacks an N-terminal extracellular domain",HPRD50.d9.s1
49,HPRD50.d11,True,Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells,HPRD50.d11.s0
50,HPRD50.d11,True,Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells,HPRD50.d11.s0
51,HPRD50.d11,True,Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells,HPRD50.d11.s0
52,HPRD50.d11,True,"This suggests that transmembrane ADAM 12, by providing docking sites for the Src homology 3 domain of p85alpha, activates PI 3-kinase by mediating its recruitment to the membrane",HPRD50.d11.s1
53,HPRD50.d12,True,AP180 binds to the C-terminal SH2 domain of phospholipase C-gamma1 and inhibits its enzymatic activity,HPRD50.d12.s0
54,HPRD50.d12,False,"In this report, we demonstrate the stable association of PLCgamma1 with AP180 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PLCgamma1, but also inhibits its enzymatic activity in a dose-dependent manner",HPRD50.d12.s1
55,HPRD50.d12,True,"In this report, we demonstrate the stable association of PLCgamma1 with AP180 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PLCgamma1, but also inhibits its enzymatic activity in a dose-dependent manner",HPRD50.d12.s1
56,HPRD50.d12,True,"In this report, we demonstrate the stable association of PLCgamma1 with AP180 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PLCgamma1, but also inhibits its enzymatic activity in a dose-dependent manner",HPRD50.d12.s1
57,HPRD50.d13,True,Here we demonstrate colocalization and direct interaction between CLIP-170 and LIS1,HPRD50.d13.s0
58,HPRD50.d13,False,"Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1
59,HPRD50.d13,False,"Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1
60,HPRD50.d13,True,"Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1
61,HPRD50.d13,False,"Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1
62,HPRD50.d13,False,"Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1
63,HPRD50.d13,False,"Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs",HPRD50.d13.s1
64,HPRD50.d13,True,"This work suggests that LIS1 is a regulated adapter between CLIP-170 and cytoplasmic dynein at sites involved in cargo-MT loading, and/or in the control of MT dynamics",HPRD50.d13.s2
65,HPRD50.d14,False,Megalin and cubilin: multifunctional endocytic receptors,HPRD50.d14.s0
66,HPRD50.d14,True,Megalin and cubilin are two structurally different endocytic receptors that interact to serve such functions,HPRD50.d14.s1
67,HPRD50.d16,True,GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress,HPRD50.d16.s0
68,HPRD50.d16,False,GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress,HPRD50.d16.s0
69,HPRD50.d16,True,GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress,HPRD50.d16.s0
70,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
71,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
72,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
73,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
74,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
75,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
76,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
77,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
78,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
79,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
80,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
81,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
82,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
83,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
84,HPRD50.d16,False,"Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis",HPRD50.d16.s1
85,HPRD50.d16,True,Recent evidence has implicated Gadd45a in inhibition of cdc2/cyclinB1 kinase and in G2/M cell cycle arrest,HPRD50.d16.s2
86,HPRD50.d16,True,"Yet, whether Gadd45b and/or Gadd45g function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established",HPRD50.d16.s3
87,HPRD50.d16,True,"Yet, whether Gadd45b and/or Gadd45g function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established",HPRD50.d16.s3
88,HPRD50.d16,False,"Yet, whether Gadd45b and/or Gadd45g function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established",HPRD50.d16.s3
89,HPRD50.d16,False,"In this work, we show that Gadd45b and Gadd45g specifically interact with the Cdk1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo",HPRD50.d16.s4
90,HPRD50.d16,True,"In this work, we show that Gadd45b and Gadd45g specifically interact with the Cdk1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo",HPRD50.d16.s4
91,HPRD50.d16,True,"In this work, we show that Gadd45b and Gadd45g specifically interact with the Cdk1/CyclinB1 complex, but not with other Cdk/Cyclin complexes, in vitro and in vivo",HPRD50.d16.s4
92,HPRD50.d16,True,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5
93,HPRD50.d16,True,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5
94,HPRD50.d16,True,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5
95,HPRD50.d16,False,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5
96,HPRD50.d16,False,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5
97,HPRD50.d16,False,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5
98,HPRD50.d16,True,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5
99,HPRD50.d16,False,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5
100,HPRD50.d16,True,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5
101,HPRD50.d16,True,"Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex",HPRD50.d16.s5
102,HPRD50.d16,False,"Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6
103,HPRD50.d16,False,"Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6
104,HPRD50.d16,True,"Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6
105,HPRD50.d16,False,"Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6
106,HPRD50.d16,False,"Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6
107,HPRD50.d16,True,"Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex",HPRD50.d16.s6
108,HPRD50.d18,False,The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn),HPRD50.d18.s0
109,HPRD50.d18,True,The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn),HPRD50.d18.s0
110,HPRD50.d18,True,The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn),HPRD50.d18.s0
111,HPRD50.d18,False,"The receptor-like protein tyrosine phosphatase DEP1, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes",HPRD50.d18.s1
112,HPRD50.d18,False,"The receptor-like protein tyrosine phosphatase DEP1, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes",HPRD50.d18.s1
113,HPRD50.d18,False,"The receptor-like protein tyrosine phosphatase DEP1, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes",HPRD50.d18.s1
114,HPRD50.d18,True,DEP1 also interacted with other members of the catenin gene family including beta-catenin and gamma-catenin,HPRD50.d18.s2
115,HPRD50.d18,False,"The interaction with p120(ctn) is likely to be direct, as the interaction occurs in K562 cells lacking functional adherens junctions and E-cadherin expression",HPRD50.d18.s3
116,HPRD50.d18,False,"Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEP1 with these proteins is specific",HPRD50.d18.s4
117,HPRD50.d18,False,"Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEP1 with these proteins is specific",HPRD50.d18.s4
118,HPRD50.d18,False,"Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEP1 with these proteins is specific",HPRD50.d18.s4
119,HPRD50.d19,False,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0
120,HPRD50.d19,True,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0
121,HPRD50.d19,False,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0
122,HPRD50.d19,True,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0
123,HPRD50.d19,False,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0
124,HPRD50.d19,True,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor,HPRD50.d19.s0
125,HPRD50.d19,False,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters,HPRD50.d19.s1
126,HPRD50.d19,False,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters,HPRD50.d19.s1
127,HPRD50.d19,False,p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters,HPRD50.d19.s1
128,HPRD50.d19,True,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex",HPRD50.d19.s2
129,HPRD50.d19,False,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex",HPRD50.d19.s2
130,HPRD50.d19,False,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex",HPRD50.d19.s2
131,HPRD50.d19,False,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex",HPRD50.d19.s2
132,HPRD50.d19,False,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex",HPRD50.d19.s2
133,HPRD50.d19,True,"Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex",HPRD50.d19.s2
134,HPRD50.d20,True,"The human Imp3 and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes",HPRD50.d20.s0
135,HPRD50.d20,True,"The human Imp3 and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes",HPRD50.d20.s0
136,HPRD50.d20,True,"The human Imp3 and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes",HPRD50.d20.s0
137,HPRD50.d20,False,We have cloned cDNAs encoding the human and mouse homologs of the yeast U3 snoRNP-associated proteins Imp3 and Imp4,HPRD50.d20.s1
138,HPRD50.d20,False,"The results of complementation experiments show that, in contrast to mouse Imp4, mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved",HPRD50.d20.s2
139,HPRD50.d20,False,"The results of complementation experiments show that, in contrast to mouse Imp4, mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved",HPRD50.d20.s2
140,HPRD50.d20,False,"The results of complementation experiments show that, in contrast to mouse Imp4, mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved",HPRD50.d20.s2
141,HPRD50.d20,False,"The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Imp3 and Imp4 proteins predominantly interact with the U3 snoRNA in 60-80S ribonucleoprotein complexes",HPRD50.d20.s3
142,HPRD50.d20,True,"The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Imp3 and Imp4 proteins predominantly interact with the U3 snoRNA in 60-80S ribonucleoprotein complexes",HPRD50.d20.s3
143,HPRD50.d20,True,"The results of density gradient centrifugation experiments show that, in contrast to hU3-55K, the human Imp3 and Imp4 proteins predominantly interact with the U3 snoRNA in 60-80S ribonucleoprotein complexes",HPRD50.d20.s3
144,HPRD50.d21,True,"In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the orexin 1 receptor (OX1R) using a heterologous system",HPRD50.d21.s0
145,HPRD50.d21,True,"In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the orexin 1 receptor (OX1R) using a heterologous system",HPRD50.d21.s0
146,HPRD50.d21,False,"In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the orexin 1 receptor (OX1R) using a heterologous system",HPRD50.d21.s0
147,HPRD50.d21,False,"In contrast to OX1R, the potency of direct activation of CB1 was not affected by co-expression with OX1R",HPRD50.d21.s1
148,HPRD50.d21,False,"In contrast to OX1R, the potency of direct activation of CB1 was not affected by co-expression with OX1R",HPRD50.d21.s1
149,HPRD50.d21,False,"In contrast to OX1R, the potency of direct activation of CB1 was not affected by co-expression with OX1R",HPRD50.d21.s1
150,HPRD50.d21,False,"In addition, electron microscopy experiments revealed that CB1 and OX1R are closely apposed at the plasma membrane level; they are close enough to form hetero-oligomers",HPRD50.d21.s2
151,HPRD50.d22,False,"GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2",HPRD50.d22.s0
152,HPRD50.d22,True,"GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2",HPRD50.d22.s0
153,HPRD50.d22,True,"GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2",HPRD50.d22.s0
154,HPRD50.d22,True,"GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2",HPRD50.d22.s0
155,HPRD50.d22,True,"GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2",HPRD50.d22.s0
156,HPRD50.d22,False,"GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2",HPRD50.d22.s0
157,HPRD50.d22,True,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1
158,HPRD50.d22,True,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1
159,HPRD50.d22,True,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1
160,HPRD50.d22,False,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1
161,HPRD50.d22,False,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1
162,HPRD50.d22,False,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1
163,HPRD50.d22,True,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1
164,HPRD50.d22,False,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1
165,HPRD50.d22,True,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1
166,HPRD50.d22,True,"Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk",HPRD50.d22.s1
167,HPRD50.d22,True,"In addition, GC-GAP contains several classic proline-rich motifs, and it interacts with the first SH3 domain of Crk and full-length Nck in vitro",HPRD50.d22.s2
168,HPRD50.d22,True,"We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3
169,HPRD50.d22,True,"We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3
170,HPRD50.d22,False,"We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3
171,HPRD50.d22,False,"We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3
172,HPRD50.d22,True,"We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3
173,HPRD50.d22,True,"We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities",HPRD50.d22.s3
174,HPRD50.d22,False,This work led to identification of a novel GTPase-activating protein (GAP) for Rho family GTPases,HPRD50.d22.s4
175,HPRD50.d22,False,"The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, Rac1, and Cdc42 in vitro",HPRD50.d22.s5
176,HPRD50.d22,False,"The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, Rac1, and Cdc42 in vitro",HPRD50.d22.s5
177,HPRD50.d22,False,"The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, Rac1, and Cdc42 in vitro",HPRD50.d22.s5
178,HPRD50.d22,False,The protein was named GC-GAP for its ability to interact with GAB proteins and its activity toward Rac and Cdc42,HPRD50.d22.s6
179,HPRD50.d22,True,The protein was named GC-GAP for its ability to interact with GAB proteins and its activity toward Rac and Cdc42,HPRD50.d22.s6
180,HPRD50.d22,True,The protein was named GC-GAP for its ability to interact with GAB proteins and its activity toward Rac and Cdc42,HPRD50.d22.s6
181,HPRD50.d22,True,Expression of GC-GAP in 293T cells led to a reduction in active Rac1 and Cdc42 levels but not RhoA,HPRD50.d22.s7
182,HPRD50.d22,True,Expression of GC-GAP in 293T cells led to a reduction in active Rac1 and Cdc42 levels but not RhoA,HPRD50.d22.s7
183,HPRD50.d22,False,Expression of GC-GAP in 293T cells led to a reduction in active Rac1 and Cdc42 levels but not RhoA,HPRD50.d22.s7
184,HPRD50.d23,True,A role for Plk1 phosphorylation of NudC in cytokinesis,HPRD50.d23.s0
185,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
186,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
187,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
188,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
189,HPRD50.d23,True,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
190,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
191,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
192,HPRD50.d23,True,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
193,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
194,HPRD50.d23,True,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
195,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
196,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
197,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
198,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
199,HPRD50.d23,False,"Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo",HPRD50.d23.s1
200,HPRD50.d23,False,"Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2
201,HPRD50.d23,False,"Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2
202,HPRD50.d23,False,"Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2
203,HPRD50.d23,False,"Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2
204,HPRD50.d23,False,"Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2
205,HPRD50.d23,False,"Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites",HPRD50.d23.s2
206,HPRD50.d23,True,These results suggest that Plk1 phosphorylation of NudC may influence cytokinesis,HPRD50.d23.s3
207,HPRD50.d24,True,Specific interaction of Egr1 and c/EBPbeta leads to the transcriptional activation of the human low density lipoprotein receptor gene,HPRD50.d24.s0
208,HPRD50.d24,False,The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway,HPRD50.d24.s1
209,HPRD50.d24,False,The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway,HPRD50.d24.s1
210,HPRD50.d24,True,The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway,HPRD50.d24.s1
211,HPRD50.d24,False,The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway,HPRD50.d24.s1
212,HPRD50.d24,True,The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway,HPRD50.d24.s1
213,HPRD50.d24,True,The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway,HPRD50.d24.s1
214,HPRD50.d25,False,TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3,HPRD50.d25.s0
215,HPRD50.d25,True,TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3,HPRD50.d25.s0
216,HPRD50.d25,False,TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3,HPRD50.d25.s0
217,HPRD50.d25,False,BACKGROUND: Both androgen receptor (AR) and orphan receptor TR2 (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines,HPRD50.d25.s1
218,HPRD50.d25,False,BACKGROUND: Both androgen receptor (AR) and orphan receptor TR2 (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines,HPRD50.d25.s1
219,HPRD50.d25,False,BACKGROUND: Both androgen receptor (AR) and orphan receptor TR2 (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines,HPRD50.d25.s1
220,HPRD50.d25,False,The interaction between AR and TR2 was assessed by glutathione-S-transferase (GST) pull-down assay and mammalian two-hybrid system assay,HPRD50.d25.s2
221,HPRD50.d25,False,The interaction between AR and TR2 was assessed by glutathione-S-transferase (GST) pull-down assay and mammalian two-hybrid system assay,HPRD50.d25.s2
222,HPRD50.d25,False,The interaction between AR and TR2 was assessed by glutathione-S-transferase (GST) pull-down assay and mammalian two-hybrid system assay,HPRD50.d25.s2
223,HPRD50.d26,True,The protein pVHL functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor Hif1 alpha for proteasomal degradation during normoxia,HPRD50.d26.s0
224,HPRD50.d26,True,"We establish that pVHL binds to Tat-binding protein-1 (TBP-1), a component of the 19S regulatory complex of the proteasome",HPRD50.d26.s1
225,HPRD50.d26,False,"We establish that pVHL binds to Tat-binding protein-1 (TBP-1), a component of the 19S regulatory complex of the proteasome",HPRD50.d26.s1
226,HPRD50.d26,True,"We establish that pVHL binds to Tat-binding protein-1 (TBP-1), a component of the 19S regulatory complex of the proteasome",HPRD50.d26.s1
227,HPRD50.d26,True,TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo,HPRD50.d26.s2
228,HPRD50.d26,True,TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo,HPRD50.d26.s2
229,HPRD50.d26,True,TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo,HPRD50.d26.s2
230,HPRD50.d26,False,TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo,HPRD50.d26.s2
231,HPRD50.d26,False,TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo,HPRD50.d26.s2
232,HPRD50.d26,False,TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo,HPRD50.d26.s2
233,HPRD50.d26,True,Overexpression of TBP-1 promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of TBP-1,HPRD50.d26.s3
234,HPRD50.d26,True,Overexpression of TBP-1 promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of TBP-1,HPRD50.d26.s3
235,HPRD50.d26,False,Overexpression of TBP-1 promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of TBP-1,HPRD50.d26.s3
236,HPRD50.d26,True,Blockade of TBP-1 expression by small interfering RNA (siRNA) causes prolonged degradation kinetics of Hif1 alpha,HPRD50.d26.s4
237,HPRD50.d26,False,Several distinct mutations in exon 2 of VHL disrupt binding of pVHL to TBP-1,HPRD50.d26.s5
238,HPRD50.d26,True,Several distinct mutations in exon 2 of VHL disrupt binding of pVHL to TBP-1,HPRD50.d26.s5
239,HPRD50.d26,True,Several distinct mutations in exon 2 of VHL disrupt binding of pVHL to TBP-1,HPRD50.d26.s5
240,HPRD50.d26,False,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha",HPRD50.d26.s6
241,HPRD50.d26,False,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha",HPRD50.d26.s6
242,HPRD50.d26,False,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha",HPRD50.d26.s6
243,HPRD50.d26,False,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha",HPRD50.d26.s6
244,HPRD50.d26,False,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha",HPRD50.d26.s6
245,HPRD50.d26,True,"A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha",HPRD50.d26.s6
246,HPRD50.d26,False,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7
247,HPRD50.d26,False,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7
248,HPRD50.d26,True,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7
249,HPRD50.d26,False,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7
250,HPRD50.d26,True,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7
251,HPRD50.d26,False,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7
252,HPRD50.d26,False,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7
253,HPRD50.d26,False,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7
254,HPRD50.d26,False,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7
255,HPRD50.d26,True,"Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors",HPRD50.d26.s7
256,HPRD50.d27,True,"Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0
257,HPRD50.d27,True,"Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0
258,HPRD50.d27,False,"Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0
259,HPRD50.d27,False,"Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0
260,HPRD50.d27,True,"Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0
261,HPRD50.d27,True,"Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells",HPRD50.d27.s0
262,HPRD50.d27,False,"Three SR-rich proteins were identified that interact with the C-terminus of Pnn: SRp75 and SRm300, known components of spliceosome machinery, and a novel 130-kDa nuclear protein, SRrp130",HPRD50.d27.s1
263,HPRD50.d29,True,Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription,HPRD50.d29.s0
264,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1
265,HPRD50.d29,False,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1
266,HPRD50.d29,False,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1
267,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1
268,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1
269,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1
270,HPRD50.d29,False,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1
271,HPRD50.d29,False,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1
272,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1
273,HPRD50.d29,True,"Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins",HPRD50.d29.s1
274,HPRD50.d29,False,Dnmt3a is modified by SUMO-1 in vivo and in vitro and the region of Dnmt3a responsible for interaction maps to the N-terminal regulatory domain,HPRD50.d29.s2
275,HPRD50.d29,True,Dnmt3a is modified by SUMO-1 in vivo and in vitro and the region of Dnmt3a responsible for interaction maps to the N-terminal regulatory domain,HPRD50.d29.s2
276,HPRD50.d29,False,Dnmt3a is modified by SUMO-1 in vivo and in vitro and the region of Dnmt3a responsible for interaction maps to the N-terminal regulatory domain,HPRD50.d29.s2
277,HPRD50.d29,True,"Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases (HDAC1/2), but not with another interaction partner, Dnmt3b",HPRD50.d29.s3
278,HPRD50.d29,False,"Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases (HDAC1/2), but not with another interaction partner, Dnmt3b",HPRD50.d29.s3
279,HPRD50.d29,False,"Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases (HDAC1/2), but not with another interaction partner, Dnmt3b",HPRD50.d29.s3
280,HPRD50.d30,True,The tyrosine kinase Tyk-2 is physically associated with the Type I interferon (IFN) receptor complex and is rapidly activated during IFN alpha stimulation,HPRD50.d30.s0
281,HPRD50.d30,False,The tyrosine kinase Tyk-2 is physically associated with the Type I interferon (IFN) receptor complex and is rapidly activated during IFN alpha stimulation,HPRD50.d30.s0
282,HPRD50.d30,True,The tyrosine kinase Tyk-2 is physically associated with the Type I interferon (IFN) receptor complex and is rapidly activated during IFN alpha stimulation,HPRD50.d30.s0
283,HPRD50.d31,True,Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation,HPRD50.d31.s0
284,HPRD50.d31,True,We show here that Cdc25 phosphatase associates with raf1 in somatic mammalian cells and in meiotic frog oocytes,HPRD50.d31.s1
285,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0
286,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0
287,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0
288,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0
289,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0
290,HPRD50.d32,False,"Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease",HPRD50.d32.s0
291,HPRD50.d32,False,"Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1
292,HPRD50.d32,True,"Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1
293,HPRD50.d32,True,"Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1
294,HPRD50.d32,True,"Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1
295,HPRD50.d32,True,"Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1
296,HPRD50.d32,False,"Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain",HPRD50.d32.s1
297,HPRD50.d32,False,"Overall, the results indicate that specific vascular cell-derived PGs differentially interact with A beta, and that the interactions of highest affinity occur between A beta and binding sites on both the core protein and glycosaminoglycan chains of perlecan",HPRD50.d32.s2
298,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan",HPRD50.d32.s3
299,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan",HPRD50.d32.s3
300,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan",HPRD50.d32.s3
301,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan",HPRD50.d32.s3
302,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan",HPRD50.d32.s3
303,HPRD50.d32,False,"In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan",HPRD50.d32.s3
304,HPRD50.d32,False,"Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta (1-28) produced strong immunoreactivity with A beta antibodies at tissue sites enriched in perlecan which was partially removed by pretreatment with heparitinase, but not by chondroitin ABC lyase",HPRD50.d32.s4
305,HPRD50.d32,False,"[35S]-Sulfate labeled proteoglycans (PGs) derived from cultured ECs and SMCs bound to affinity columns containing A beta (1-28) or (1-40), with virtually no binding to A beta (40-1) (reverse peptide), beta-amyloid precursor protein (410-429), or bovine serum albumin",HPRD50.d32.s5
306,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
307,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
308,HPRD50.d32,True,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
309,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
310,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
311,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
312,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
313,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
314,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
315,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
316,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
317,HPRD50.d32,True,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
318,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
319,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
320,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
321,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
322,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
323,HPRD50.d32,True,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
324,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
325,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
326,HPRD50.d32,False,"Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan",HPRD50.d32.s6
327,HPRD50.d33,True,"Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D",HPRD50.d33.s0
328,HPRD50.d33,False,"Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D",HPRD50.d33.s0
329,HPRD50.d33,True,"Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D",HPRD50.d33.s0
330,HPRD50.d33,True,"However, cytokines, in particular IL-2 and IL-4, potentiated the DNA synthesis induced by cross-linking of CD53",HPRD50.d33.s1
331,HPRD50.d33,True,"However, cytokines, in particular IL-2 and IL-4, potentiated the DNA synthesis induced by cross-linking of CD53",HPRD50.d33.s1
332,HPRD50.d33,False,"However, cytokines, in particular IL-2 and IL-4, potentiated the DNA synthesis induced by cross-linking of CD53",HPRD50.d33.s1
333,HPRD50.d34,False,The human apoB mRNA editing protein is a cytidine deaminase showing structural homology to some known mammalian and bacteriophage deoxycytidylate deaminases,HPRD50.d34.s0
334,HPRD50.d34,False,The fact that the apoB mRNA editing protein also exists as a homodimer has important implications for the mechanism of apoB mRNA editing in humans,HPRD50.d34.s1
335,HPRD50.d34,False,The fact that the apoB mRNA editing protein also exists as a homodimer has important implications for the mechanism of apoB mRNA editing in humans,HPRD50.d34.s1
336,HPRD50.d34,False,The fact that the apoB mRNA editing protein also exists as a homodimer has important implications for the mechanism of apoB mRNA editing in humans,HPRD50.d34.s1
337,HPRD50.d35,False,"Assignment of Etfdh, Etfb, and Etfa to chromosomes 3, 7, and 13: the mouse homologs of genes responsible for glutaric acidemia type II in human",HPRD50.d35.s0
338,HPRD50.d35,False,"We used cDNA probes for the Etfdh, Etfb, and Etfa genes to determine localization of these mouse genes to chromosomes 3, 7, and 13",HPRD50.d35.s1
339,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
340,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
341,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
342,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
343,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
344,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
345,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
346,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
347,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
348,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
349,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
350,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
351,HPRD50.d38,False,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
352,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
353,HPRD50.d38,True,"Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family",HPRD50.d38.s0
354,HPRD50.d38,False,"Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links",HPRD50.d38.s1
355,HPRD50.d38,False,"Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links",HPRD50.d38.s1
356,HPRD50.d38,False,"Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links",HPRD50.d38.s1
357,HPRD50.d39,True,"A prominent isolate, designated SRcyp/CASP10, specifically interacts with the CTD not only in vivo but also in vitro",HPRD50.d39.s0
358,HPRD50.d39,False,"A prominent isolate, designated SRcyp/CASP10, specifically interacts with the CTD not only in vivo but also in vitro",HPRD50.d39.s0
359,HPRD50.d39,True,"A prominent isolate, designated SRcyp/CASP10, specifically interacts with the CTD not only in vivo but also in vitro",HPRD50.d39.s0
360,HPRD50.d39,False,SRcyp is a nuclear protein with a characteristic distribution in large irregularly shaped nuclear speckles and co-localizes perfectly with the SR domain-containing splicing factor SC35,HPRD50.d39.s1
361,HPRD50.d40,True,Transient expression of the full-length E2-2 without RSRS in U1240MG glioblastoma cells resulted in repression of FGF-1.B promoter activity,HPRD50.d40.s0
362,HPRD50.d40,True,These results suggest that the relative abundance of the two splice variants of E2-2 in brain could be an important determinant for the expression of FGF-1,HPRD50.d40.s1
